ANDA 78708, held by Teva Pharms USA. Aripiprazole.
As of Nov 16, 2026, ANDA 78708 (Aripiprazole), held by Teva Pharms USA, was first approved by FDA on Apr 28, 2015, with 6 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Apr 28, 2015 | Original application | Approved | None posted |
| Aripiprazole15MG · tablet;oral | Aripiprazole | Discontinued |
| Aripiprazole20MG · tablet;oral | Aripiprazole | Discontinued |
| Aripiprazole30MG · tablet;oral | Aripiprazole | Discontinued |
| Nov 14, 2025 | Supplement 9Labeling · Standard review | Approved | None posted |
| Nov 14, 2025 | Supplement 8Labeling · Standard review | Approved | None posted |
| Nov 14, 2025 | Supplement 6Labeling · Standard review | Approved | None posted |
| Nov 14, 2025 | Supplement 4Labeling · Standard review | Approved | None posted |
| Nov 14, 2025 | Supplement 3Labeling · Standard review | Approved | None posted |
| Nov 14, 2025 | Supplement 2Labeling · Standard review | Approved | None posted |
| Apr 28, 2015 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters